A retrospective claims analysis of combination therapy in the treatment of adult attention-deficit/hyperactivity disorder (ADHD). BMC Health Serv Res. 2009;9:95.PubMedCrossRef 5. Intuniv (package insert). Wayne: Shire Pharmaceuticals Inc.; 2011. 6. Biederman J, Melmed RD, Patel A, et al., for the SPD503 Study Group. A randomized, double-blind, placebo-controlled study of guanfacine extended
#check details randurls[1|1|,|CHEM1|]# release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics. 2008;121(1):e73–e84. 7. Sallee F, McGough J, Wigal T, et al., for the SPD503 Study Group. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009;48(2):155–65.PubMedCrossRef 8. Sallee FR, Lyne A, Wigal T, et al. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19(3):215–26.PubMedCrossRef 9. Biederman J, Melmed RD, Patel A, et al. Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD. CNS Spectr. 2008;13(12):1047–55.PubMed 10. Connor DF, Findling RL, Kollins SH, et al. Effects of guanfacine extended release on oppositional symptoms in children
aged 6–12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. CNS Drugs. 2010;24(9):755–68.PubMed 11. Faraone https://www.selleckchem.com/products/Thiazovivin.html SV, Pucci M, Coghill D. Pharmacotherapy for attention-deficit-hyperactivity disorder. US Psychiatry Rev. 2009;2(1):17–27. 12. Wilens TE, Spencer TJ. Understanding attention-deficit/hyperactivity disorder from childhood to adulthood. Postgrad Med. 2010;122(5):97–109.PubMedCrossRef 13. Vyvanse (package insert). Wayne: Shire US Reverse transcriptase Inc.; 2012. 14. Spencer TJ, Greenbaum M, Ginsberg LD, et al. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity
disorder. J Child Adolesc Psychopharmacol. 2009;19(5):501–10.PubMedCrossRef 15. Wilens TE, Youcha S, Lyne A, et al. A multisite placebo-controlled trial of morning or evening dosed extended-release guanfacine in combination with psychostimulants in children and adolescents with ADHD. 65th Annual Meeting of the Society of Biological Psychiatry; 2010 May 20–22; New Orleans. 16. US Department of Health and Human Services. Guidance for industry: in vivo drug metabolism/drug interaction studies—study design, data analysis, and recommendations for dosing and labeling. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072119.pdf. Accessed 26 Oct 2012. 17. Pennick M. Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat. 2010;6(1):317–27.PubMedCrossRef 18. Krishnan S, Moncrief S.